Skip to main content
CHOONG ANG VACCINE LABORATORY logo

CHOONG ANG VACCINE LABORATORY — Investor Relations & Filings

Ticker · 072020 ISIN · KR7072020001 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 072020

About CHOONG ANG VACCINE LABORATORY

http://www.cavaccine.com

Established in 1968, Choong Ang Vaccine Laboratory (CAVAC) is a company specializing in the research, development, manufacture, and sale of animal health products. The company's portfolio includes a wide range of vaccines designed to prevent diseases in various animal species. These products cater to livestock such as cattle and chickens, as well as companion animals including dogs, cats, and rabbits, and also extend to fish. In addition to its core vaccine business, CAVAC also produces other pharmaceutical products and feed additives for the animal health market. The company is recognized for its long-standing presence and pioneering role in the development of animal vaccines.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled 분기보고서 (Quarterly Report) for the period Jan 1, 2026 to Mar 31, 2026, issued to the Financial Services Commission and Korea Exchange. It contains detailed company overview, business description, financial data, production and sales figures, risk management, contracts, and R&D activities. This is the full interim/quarterly report itself (actual financial statements and analysis), not merely an announcement or summary. It matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled '영업(잠정)실적(공정공시)' which translates to 'Preliminary Operating Results (Fair Disclosure)'. It provides financial performance data for the first quarter of 2026, including sales, operating profit, and net income, compared to previous quarters and the same period last year. The document explicitly states that these are preliminary figures prepared under Korean IFRS and have not been audited or reviewed by external auditors. The length of the document is 2273 characters, which is relatively short and the content is focused on preliminary financial results rather than a full comprehensive report. There is no indication that this is a full interim or quarterly report with detailed financial statements and analysis, but rather a preliminary earnings announcement. Therefore, the document fits best as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Q1 2026
2026-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” reporting an executive’s share ownership and trading (장내매수) details to the Securities and Futures Commission and Korea Exchange. It provides insider transaction dates, share counts before/after, and purchase prices. This matches an insider trading report by a company director or major shareholder. Therefore, it is a Director’s Dealing filing.
2026-04-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean “임원ㆍ주요주주 특정증권등 소유상황보고서” (Report of officers and major shareholders’ holdings and changes in specific securities) filed with the Korea Exchange and the Securities and Futures Commission. It provides personal share ownership details, transaction dates, quantities, and changes for an executive. This is a classic insider transaction report rather than a corporate repurchase notice, annual report, or earnings release. Thus it falls under Director’s Dealing (insider trading) filings.
2026-04-28 Korean
기업가치제고계획(자율공시) (2026년 주식회사 중앙백신연구소 기업가치 제고 계획)
Regulatory Filings Classification · 52% confidence The document is a voluntary self-disclosure (“자율공시”) of a corporate value enhancement plan by 주식회사 중앙백신연구소. It is not an annual or interim report, earnings release, audit report, or dividend notice. It is a strategic plan document filed as a regulatory announcement in Korea that does not fall under any more specific category. Therefore, it is best classified under the fallback “Regulatory Filings” category (RNS).
2026-03-25 Korean
대표이사변경
Board/Management Information Classification · 90% confidence The document is a formal announcement of the change in the company’s 대표이사 (CEO/representative director), detailing the outgoing and incoming directors, board resolution date, attendance, and career details. This clearly falls under Board/Management Information (changes in management positions).
2026-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.